Video

RVL Pharmaceuticals: Shifting toward ocular aesthetics

COO JD Schaub provides an overview of how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®.

JD Schaub, chief operating officer at RVL Pharmaceuticals, provides an overview of how the company has shifted toward focusing on ocular aesthetics, along with the sole purpose to fully focus on UPNEEQ®, a prescription eye drop.

See more ASCRS coverage

Related Videos
Image credit: ©Ophthalmology Times
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Vikas Chopra, MD, at AAO 2024: The role of MIGS in earlier intervention and safer techniques
© 2025 MJH Life Sciences

All rights reserved.